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Here, we investigated themolecular mechanism underlying the changes in the distribution of nucle-
olin. Our study identiﬁed PI3K/Akt signaling as an essential pathway regulating the distribution of
nucleolin. Furthermore, nucleolin can interact with phospho-PI3K-p55, and changes in the distribu-
tion of nucleolin were related to its phosphorylation. Subsequently, we analyzed the correlation of
VEGF and nucleolin, and found that distribution of nucleolin related to metastatic potential. Finally,
blocking cell surface nucleolin inﬂuences the process of epithelial–mesenchymal transitions. This
indicates that nucleolin may be a novel cancer therapy target and a predictive marker for tumor
migration in colorectal carcinoma.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Worldwide, colorectal cancer is the fourth most common tumor
in men and the third most common in women [11, 23]. Tumor
metastasis remains the principal cause of high mortality rate and
poor prognosis in patients with colorectal cancer; colorectal carci-
noma that is localized within the colon or has only spread to the
lymph nodes is curable by surgery with or without chemotherapy,
and has a 5-year survival rate of 70% and 90%, respectively. How-
ever, cancer that has metastasized to distant sites is generally
incurable and has a 5-year survival rate of 12% [30]. Hence, many
studies aimed at identifying a novel predictor or therapy target
for colorectal carcinoma have been reported [17,31].
Nucleolin is a multifunctional protein with well-characterized
roles in the organization of nucleolar chromatin, packaging of
pre-rRNA, transcription of rDNA, and ribosome assembly [1]. The
importance of cell surface nucleolin has been suggested by studiesshowing that functional blockade or down-regulation of cell sur-
face nucleolin in endothelial cells inhibits migration and capil-
lary-tubule formation and causes endothelial cell apoptosis
[37].Targeting nucleolin on the plasma membrane of cancer cells
seems to be an effective approach to inhibit cancer cell growth
and angiogenesis in various in vitro and in vivo experimental mod-
els [26]. In recent years, studies have suggested that high levels of
nucleolar expression of nucleolin are associated with a better prog-
nosis in pancreatic ductal adenocarcinoma patients [25], and that
nucleolin on the cell surface may be a novel cancer therapy target
(Abdelmohsen and Gorospe, 2012), [38,39].
Previous studies have indicated that VEGF can increase the cell
surface nucleolin expression in human microvascular endothelial
cells [16]. VEGF plays a major role in tumor angiogenesis and
migration; its expression is inversely correlated with survival of
patients in many human cancers, including colorectal carcinomas.
Both cell surface nucleolin and VEGF are upregulated in different
types of cancer and have been implicated in migration progression
[3,4].
Here, we showed that VEGF, through the VEGFR, leads to phos-
phorylation of nucleolin and that this then results in nucleolin
localization to the membrane. We also found that distribution of
nucleolin is related to the phosphorylation states of nucleolin.
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and cytosolic nucleolin were related to tumor metastasis. Thus,
nucleolin may be a novel theraputic target for colorectal cancer,
while the distribution of nucleolin may be a predictive indicator
in clinical diagnosis.
2. Materials and methods
2.1. Materials
Recombinant human VEGF165 was purchased from PeproTech
(Suzhou, China). The anti-nucleolin, anti-PI3K, and anti-Akt poly-
clonal antibodies were obtained from ProteinTech Group, Inc.
(Wuhan, China). The phospho-Akt (Thr308) and phospho-PI3
kinase P85 (Tyr458)/P55 (Tyr199) antibodies were purchased from
Cell Signaling Technology, Inc. (Danvers, MA). The phosphoserine/
threonine/tyrosine antibody was purchased from GeneTex Interna-
tional Corporation (CA, USA). Anti-Thr76/Thr84-phosphorylated
nucleolin antibody was purchased from BioLegend (San Diego,
USA). The secondary antibody (goat anti-rabbit IgG) was purchased
from Santa Cruz Biotechnology (Heidelberg, Germany). Tumor
microarrays were purchased from Biomax US (MD, USA). HB19
(Cell surface nucleolin inhibitor) and 9 Args were synthetized by
Shanghai Science Peptide (Shanghai, China). All other kits or
reagents were purchased from the Beyotime Institute of Biotech-
nology (Shanghai, China).
2.2. Immunoﬂuorescence
Cells were ﬁxed with 4% paraformaldehyde, and then blocked
with PBS containing 10% normal goat serum. Cells were then
stained with anti-nucleolin polyclonal antibody for 30 min at
37 C, and then stained with Cy3-conjugated secondary antibody
for 30 min at 37 C. Then those samples were re-stained by Hoch-
est 33258 for 15 min at 37 C. All immunoﬂuorescence images
were obtained using an Olympus BX51 microscope equipped with
either a 20 or a 40 objective lens (Olympus) and a DP 50 camera
(Olympus). Images were processed using DPC controller software
(Olympus).
2.3. Fluorescence-activated cell-sorting (FACS) analysis
After treatment, cells were trypsinized with 0.02% EDTA, and
resuspended in PBS supplemented with 0.1% bovine serum albu-
min. Cells were incubated with anti-nucleolin antibody for
30 min on ice, and then incubated on ice with anti-rabbit second-
ary antibody conjugated to Cy3. Then, cells were directly analyzed
using a FACScan (Becton Dickinson, San Jose, CA).
2.4. Subcellular fractionation
Subcellular fractions of cells comprising cytosolic, nuclear, and
cell membrane extracts were prepared as follows. Cell monolayers
in 100-mm plates were washed extensively with PBS before being
scraped and pelleted. Washed cells (2  106) were then used for
extraction of cytosolic, nuclear, and cell membrane proteins using
a Membrane and Cytosol Protein Extraction Kit and a Nuclear and
Cytoplasmic Protein Extraction Kit according to the manufacturer’s
recommendations. These samples were then analyzed by Western
blot or co-immunoprecipitation analysis.
2.5. Co-immunoprecipitation assay
Cells were resuspended in ice-cold RIPA (Radio-Immunoprecip-
itation Assay) cell lysis buffer containing 1 mM PMSF (Phen-ylmethanesulfonyl ﬂuoride) and incubated for 30 min on ice;
lysates were then centrifuged at 18000g for 30 min at 4 C and
the supernatants (500 mg) incubated for 2 h at 4 C with 2 mg of
anti-nucleolin antibody. Concurrently, 2 mg of rabbit IgG was used
as the control. Immunoprecipitated samples were washed three
times with RIPA buffer; these samples as well as pre-immunopre-
cipitated samples (50 mg) were subjected to Western blotting
analysis using an anti-nucleolin and an anti-PI3K antibody.
2.6. Immunohistochemical staining and assessment of VEGF
and nucleolin expression
Tissues were dewaxed and antigens retrieved using high pres-
sure for 3 min. Then, the activity of endogenous peroxidases was
blocked using 3% hydrogen peroxide for 10 min at room tempera-
ture. After immersion in normal goat serum for 30 min at 37 C, tis-
sues were subjected to primary antibody incubation at 4 C
overnight. Subsequently, sections were washed with PBS for
15 min at room temperature and incubated with secondary anti-
body that had been labeled with biotin for 30 min at 37 C. After
washing with PBS for 15 min at room temperature, the sections
were incubated with horseradish peroxidase (HRP) complex for
30 min at 37 C and visualized using diaminobenzidine (DAB).
All immunohistochemical images were obtained using an
Olympus BX51 microscope equipped with either a 20, a 40, or
100 objective lens (Olympus) and a DP 50 camera (Olympus).
Images were processed using DPC controller software (Olympus).
The immunohistochemical staining was evaluated using a semi-
quantitative scoring method. The scores were decided by two
pathologists independently. The total nucleolin and VEGF staining
was scored as per staining intensity: no staining (0), light positive
staining (1), medium positive staining (2), and strong positive
staining (3). The positively stained area was scored as: <5% (0),
5–25% (1), 26–50% (2), 51–75% (3), and >75% (4). A ﬁnal score
was calculated by multiplying the intensity score by the expression
score and the rating (from 0 to 12) was determined for each case.
2.7. Statistical analysis
Each experiment was performed at least three times indepen-
dently. The associations of VEGF and nucleolin with clinicopatho-
logical parameters were generated using a paired t-test or
one-way ANOVA analyses implemented in GraphPad Prism 5
(GraphPad, San Diego, CA). Statistical signiﬁcance was deﬁned as
P < 0.05.
3. Results
3.1. VEGF changes the distribution of nucleolin in colon cancer cells
In order to investigate the function of VEGF in the distribution
of nucleolin expression in colon cancer, HCT116 cells and DLD-1
cells treated with 0, 5, 10, or 20 ng/ml VEGF for 24 h were har-
vested for FACS analysis. We found that VEGF increased nucleolin
expression on the cell surface of HCT116 and DLD-1 cells, in a con-
centration-dependent manner (Fig. 1A). To further assess the regu-
lation of nucleolin distribution in colon cells by VEGF, HCT116 and
DLD-1 cells were stained with an anti-nucleolin antibody for
immunoﬂuorescence analysis. As shown in Fig. 1B, we found that
cell surface nucleolin was increased after VEGF treatment, in a
dose-dependent manner, and there was no change in the mRNA
level of nucelolin (Supplement Fig. 2).
To further conﬁrm that VEGF can change the distribution of
nucleolin in colon cancer cells, we treated HCT116 and DLD-1
cells with different doses of VEGF; after 24 h, we separated the
Fig. 1. VEGF changes the distribution of nucleolin in colon cancer cells. (A) Flow cytometry showed that VEGF treatment of cells increased cell surface nucleolin expression in
HCT116 cells (Left) and DLD-1 cells (Right). (B) Immunoﬂuorescence analysis cell surface nucleolin after cells were treated with VEGF in HCT116 cells (Up) and DLD-1 cells
(Down). (C) The differences in the distribution of nucleolin expression were analyzed after treatment of cells with the indicated dose of VEGF in HCT116 cells (Up) and DLD-1
cells (Down).
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nucleolin in the cytosolic, nuclear, and cell membrane extracts by
Western blotting. As shown in Supplement Fig. 1, the separation
efﬁciency of those kits was detected. We found that VEGF clearly
increased nucleolin levels in the cell membrane and cytoplasmic
fractions, while nucleolin levels in the nucleus was decreased,
and the total nucleolin remained unchanged in both HCT116 and
DLD-1 cells (Fig. 1C).
3.2. VEGF changes the distribution of nucleolin via the PI3K/Akt
pathway
It has been suggested that the migration of nucleolin in the
cytosol and nucleus to the cell membrane occurs via the PI3K/
Akt pathway [20]. We tested this suggestion: HCT116 cells wereFig. 2. VEGF changes the distribution of nucleolin via the PI3K/Akt pathway. (A) Treat
nucleolin. (B) Expression of cell surface nucleolin was determined by immunoﬂuores
LY294002. (C) The distribution of nucleolin and cell membrane extracts as well as total n
increase in the phosphorylation of Akt. (E) LY294002 treatment reduced the VEGF-med
Fig. 3. Distribution of nucleolin is related to the phosphorylation states of nucleolin. (A
PI3K-p55. Normal IgG was as the control. (C) VEGF increase nucleolin phosphoryla
phosphorylation. Normal IgG was as the control. (E) Nucleolin phosphorylation is relate
colorectal carcinoma and normal lymph node. Normal IgG was as the control.cultured with 50 lM LY294002 (PI3K inhibitor) for 5 h, and then
treated with VEGF; 24 h later, cells were harvested for FACS anal-
ysis. As shown in Fig. 2A, the cell surface nucleolin levels were
decreased when cells were pretreated with LY294002, as compared
to cells not treated with LY294002, and there was no change in the
mRNA level of nucelolin (Supplement Fig. 3). This indicated that
blocking the PI3K/Akt pathway can reduce the cell surface nucleo-
lin level effectively in VEGF-treated cells.
Anti-nucleolin staining by immunoﬂuorescence analysis in
HCT116 cells further supported this ﬁnding: we found that
LY294002 clearly blocked the VEGF-mediated distribution of
nucleolin at the cell surface (Fig. 2B).
We treated HCT116 cells with VEGF and/or LY294002; after
24 h, we separated the subcellular fraction of HCT116 cells, and
analyzed the expression of nucleolin in the cytosolic, nuclear,ment of cells with LY294002 reduced the VEGF-mediated increase in cell surface
cence analysis after cells were treated with VEGF, following pre-treatment with
ucleolin levels were analyzed using Western blotting. (D) VEGF treatment caused an
iated phosphorylation of Akt.
) VEGF increased PI3K-p55 phosphorylation. (B) Nucleolin interacts with phospho-
tion. Normal IgG was as the control. (D) VEGF increase cell surface nucleolin
d to tumor stage. Lymph node metastases have higher phosphorylation level than
Fig. 4. Distribution of nucleolin is associated with tumor metastasis. (A) VEGF and nucleolin expression in normal colon, an adenocarcinoma group, and a metastases group.
(B) Immunohistochemical staining of VEGF (top) and nucleolin (bottom) in normal colon (left), adenocarcinoma (middle), and metastases (right). (C) VEGF (left) and nucleolin
(right) expression was investigated in clinical colorectal cancer samples. Immunohistochemical staining of VEGF and nucleolin in normal colon (top), adenocarcinoma
(middle), and lymph node metastases and liver metastases (bottom) indicated that distribution of nucleolin correlates with tumor metastasis.
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by Western blotting. We found that the nucleolin levels in the
cytosolic and cell membrane fractions decreased, while nuclear
nucleolin levels increased, without changes in total nucleolin levels
after LY294002 treatment. This indicated that LY294002 blocked
the distribution of nucleolin from the nucleus (Fig. 2C).We next evaluated the phosphorylation states of Akt in HCT116
cells. As shown in Fig. 2D, the phosphorylation levels of Akt
increased with VEGF treatment in a concentration-dependent
manner, while total Akt levels remained unchanged. After treat-
ment with LY294002, the phosphorylation of Akt was markedly
decreased (Fig. 2E).
Table 1
Clinicopathological association of nucelolin with colorectal carcinoma.
Factors Number of patients Average score P value
Group
Adenocarcinoma 30 3.43 ± 0.55 0.49
Metastatic adenocarcinoma 30 4.03 ± 0.65
Gender
Male 22 3.68 ± 0.69 0.47
Female 8 2.75 ± 0.86
Age
<60 years 21 2.91 ± 0.63 0.15
P60 years 9 4.67 ± 1.05
Differentiation
Well 12 3.83 ± 0.90 0.25
Moderate 27 4.74 ± 0.70
Poor 15 3.00 ± 0.64
Clinical stage
I 5 2.60 ± 1.03 0.52
II 16 4.17 ± 0.79
III 6 4.67 ± 1.50
IV 3 2.25 ± 1.32
Clinical and TNM stagings were according to American Joint Committee on Cancer:
AJCC Cancer Staging Manual, 6th edition.
Table 2
Clinicopathological association of VEGF with colorectal carcinoma.
Factors Number of patients Average score P value
Group
Adenocarcinoma 30 4.93 ± 0.40 0.02
Metastatic adenocarcinoma 30 6.80 ± 0.70
Gender
Male 22 5.18 ± 0.48 0.66
Female 8 4.75 ± 0.94
Age
<60 years 21 4.52 ± 0.49 0.16
P60 years 9 5.78 ± 0.68
Differentiation
Well 12 4.58 ± 0.73 0.46
Moderate 27 5.29 ± 0.53
Poor 15 6.00 ± 0.84
Clinical stage
I 5 3.40 ± 0.87 0.47
II 16 5.44 ± 0.60
III 6 5.00 ± 1.03
IV 3 5.00 ± 2.00
Clinical and TNM stagings were according to American Joint Committee on Cancer:
AJCC Cancer Staging Manual, 6th edition.
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nucleolin
It has been demonstrated that nucleolin physically interacts
with PI3K [18]; therefore, we tested whether VEGF increases
PI3K phosphorylation levels in HCT116 cells. As shown in Fig. 3A,
VEGF promoted PI3K-P55 phosphorylation, while total PI3K and
nucleolin levels remained unchanged in HCT116 cells.
Given that nucleolin interacts with PI3K, we tested its phos-
phorylation subunits, and found that nucleolin interacts with the
phospho-PI3K-p55 subunit (Fig. 3B). This indicated that nucleolin
interacts with phosphorylated p55 in the cell nucleus and then
translocates from the nucleus to the cytosol and cell membrane.
We next tested the phosphorylation state of nucleolin in
HCT116 cells, by immunoprecipitating total nucleolin, and then
analyzing the phosphorylation state of nucleolin using a phospho-
serine/threonine/tyrosine antibody. After treatment of cells with
VEGF, we found that the phosphorylation of nucleolin increased.We next tested whether LY294002 could block the nucleolin
phosphorylation; we found that LY294002 could reduce the
VEGF-mediated increase in nucleolin phosphorylation (Fig. 3C).
Subsequently, we analyzed the correlation between different phos-
phorylation states of nucleolin and differences in the distribution
of nucleolin were analyzed. We found that distribution of nucleolin
was related to the phosphorylation state of nucleolin in HCT116
cells; phosphorylation of nucleolin was only observed in the cyto-
solic and cell membrane extracts, but not in nuclear nucleolin. Fur-
thermore, cytosolic and cell membrane extracts demonstrated
greater levels of nucleolin phosphorylation after VEGF treatment,
but this phosphorylation was blocked when LY294002 was added
(Fig. 3D).
In order to test whether different stages of colorectal carcinoma
show different phosphorylation levels of nucleolin, we analyzed
the nucleolin phosphorylation level in colorectal carcinoma sam-
ples and compared these levels with those in lymph node metasta-
ses. We found that lymph node metastases had higher nucleolin
phosphorylation levels compared to colorectal carcinoma.
Then, the phosphorylation state of nucleolin in different distri-
butions was determined by separating colorectal carcinoma and
lymph node metastases tissue. We found that the cytosolic and cell
membrane extracts demonstrated higher phosphorylation levels of
nucleolin in the lymph node metastases than those in colorectal
carcinoma (Fig. 3F). It has been proved that Thr76/Thr84-phos-
phorylated nucleolin play a role in process of tumors, so we tested
whether the expression of phospho-Thr76/Thr84 nucleolin chan-
ged with VEGF stimulation. As shown in Supplement Fig. 4, VEGF
increased phospho-Thr76/Thr84 of nucleolin, while treatment with
LY294002 inhibited the effects of VEGF.
3.4. Distribution of nucleolin is association with tumor metastasis
To study the role of VEGF and nucleolin in colorectal carcinoma
and metastases, we assessed the levels of VEGF and nucleolin
expression in colorectal carcinoma using a tissue microarray. As
shown in Fig. 4A and B, there was no difference between normal
colon tissue, colon adenocarcinoma tissue, and colon metastases
in terms of immunohistochemical staining of total nucleolin. No
signiﬁcant difference was observed between well, moderately,
and poorly differentiated carcinoma tissues; different clinical
stages showed no signiﬁcant differences in total nucleolin expres-
sion (Table 1). Statistical analysis indicated that VEGF expression
was signiﬁcantly lower in colon adenocarcinoma than in metasta-
ses (P = 0.0241; Table 2).
We demonstrated that total nucleolin expression levels were
not statistically signiﬁcantly different between the adenocarci-
noma group and the metastases group, which suggested that
the expression of total nucleolin does not change with tumor
metastasis.
To further explore the roles of nucleolin distribution in colorec-
tal carcinoma metastasis, clinicopathological association analyses
were speciﬁcally performed for colorectal carcinoma and metasta-
ses. Along with the increase in metastatic capacity from colorectal
carcinoma, through lymph node metastases to liver metastases,
the metastatic colorectal carcinoma showed more cytosolic stain-
ing and less nuclear staining for nucleolin (Fig. 4C).
3.5. Inhibition of cell surface nucleolin by HB19 inhibits EMT in colon
cancer cells
Thus far, we have shown that inhibition of the migration of
nucleolin to the cell surface is associated with a greater risk of
tumor metastasis. Then, we investigated whether inhibition of cell
surface nucleolin would affect the process of EMT in colon cancer
cells. As shown in Fig. 5A and Supplement Fig. 5, we conﬁrmed that
Fig. 5. Inhibition of cell surface nucleolin by HB19 inhibits the process of epithelial–mesenchymal transitions (EMT) in colon cancer cells. (A) Inhibition of cell surface
nucleolin by HB19. 9R was as the control. (B) Morphological changes after HCT116 cells were treated with HB19 and/or VEGF. (C) Representative immunoﬂuorescence images
of staining for E-cadherin (above) and FSP1 (below) in serum-starved HCT116 cells treated with HB19 and/or VEGF. (D) Biomarkers for EMT: vimentin, FSP1, and E-cadherin
were analyzed by Western blotting. (E) Quantiﬁcation of cell migration by the transwell assay; data from three independent experiments are shown (P < 0.05).
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expression in HCT116 cells. 9R (9 Args) was as the control of
HB19. Treatment with HB19 promoted morphological changes in
these cells that were characterized by loss of the ‘‘ﬁbroblastoid-
like’’ phenotype and acquisition of an epithelial-like compact mor-
phology (Fig. 5B). As shown in Fig. 5C, immunoﬂuorescence stain-
ing revealed that HB19 upregulated expression of the epithelialmaker E-cadherin and decreased expression of the mesenchymal
maker ﬁbroblast-speciﬁc protein 1 (FSP1) in HCT116 cells.
We next analyzed cells treated with VEGF and/or HB19 with
biomarkers for EMT: vimentin, FSP1and E-cadherin (Fig. 5D).
HB19 markedly reduced vimentin and FSP1 expression, and
increased E-cadherin expression in HCT116 cells, and also inhib-
ited the changes caused by VEGF treatment. Furthermore, we
Fig. 6. Schematic representation of the proposed mechanism leading to nucleolin distribution and phosphorylation upon VEGF stimulation. Binding of exogenous VEGF to its
receptor, VEGFR, leads to PI3K/Akt pathway activation and PI3K-p55 phosphorylation. Activated PI3K-p55 interacts with nucleolin, either directly or indirectly, causing
phosphorylation of nucleolin and a change in nucleolin distribution.
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VEGF (Supplement Fig. 6).
Then, metastatic capacity of cells treated with VEGF and/or
HB19 were analyzed by the transwell assays. As shown in Fig. 5E,
VEGF signiﬁcantly enhanced the metastatic capacity of HCT116
cells, while HB19 treatment decreased the metastatic capacity of
these cells (P < 0.001). It was also showned that HB19 treatment
was able to abolish the effects of VEGF on the metastatic capacity
of HCT116 cells.
4. Discussion
Colorectal carcinoma is one of the most common cancers
worldwide [41], hence, a number of prognostic and predictive
indicators are used to guide therapy in patients with colorectal
carcinoma. Nucleolin is a protein that is overexpressed on the
surface of tumor and endothelial cells. Recent studies have
underlined the involvement of cell surface nucleolin in tumor
growth and angiogenesis [14]. Cell surface nucleolin interacts
with receptors associated with malignancies, such as ErbB1, facil-
itating their activation and leading to enhanced cell growth [9].
Moreover, it binds a variety of ligands that play critical roles in
tumorigenesis and angiogenesis, such as hepatocyte growth fac-
tor [21], endostatin [33], tumor-homing peptide F3 [5], laminin
[35], P-selectin [28], and midkine [20]. The effect of these signals,
however, on the migration of nucleolin from the nucleus to the
cell surface remains unclear, and not all tumor cells express cell
surface nucleolin [34].
VEGF can increase tumour metastatic capacity and its receptor,
VEGFR, is a target for therapy. Moreover, overexpression of the
VEGFR is a marker for poor prognosis although paradoxically nei-
ther it or VEGF are useful markers for response to anti-VEGF ther-
apy. Moreover, recent studies have revealed that cell surface
nucleolin regulates human endothelial and glioma cell migration
[20]; hence, we attempted to determine whether VEGF and nucle-
olin distribution in tumors are related. In this study, we proved
that VEGF regulates the distribution of nucleolin in colon cancer
cells.
It has been suggested that both the regulation of the nucleus-
cell surface shuttling of nucleolin by phosphorylation and the
reported related physical interaction between nucleolin and PI3K,
indicates a possible direct regulation of nucleolin by PI3K [18,28].
Previous studies have proven that the distribution of nucleolin at
the cell surface is caused by phosphorylation of nucleolin [6]; we
proposed that VEGF would phosphorylate nucleolin and cause it
to move to the cell surface. VEGF can activate expression of many
downstream genes, for example, those encoding protein kinases(e.g., PKC, Akt) [12], and thus could regulate the distribution of
nucleolin by the PI3K/Akt pathway and lead to phosphorylation
of nucleolin by such protein kinases. PI3K-p55 is one of the regula-
tory subunits of PI3K, which plays an important role in the regula-
tion of PI3K activity. Previous studies have shown that PI3K-p55 is
mainly located in the nucleus and can be regulated via the PI3K/
Akt pathway [15]. In this paper, we demonstrated that nucleolin
interacts with the phospho-PI3K-p55 subunit, and that the distri-
bution of nucleolin is related to phosphorylation of nucleolin.
Nucleolin and its phosphorylation have been proved to be
involved in PRL-3-mediated cancer progression/metastasis signal-
ing [32]. In the present study, we found that nucleolin phosphory-
lation and re-location were involved in tumor metastasis. These
ﬁndings may provide some clues for tumor diagnosis and the treat-
ment of tumor metastasis.
Recently, studies have shown that cytoplasmic staining and
nucleolar staining of nucleolin correlated with patients’ prognosis
in gastric cancer [27]. In this paper, we demonstrated that lymph
node metastases samples show more cell cytoplasmic staining
for nucleolin than those with adenocarcinoma in situ. This indi-
cated that nucleolin distribution may be related to the process of
metastasis in colorectal carcinoma. Other studies have demon-
strated that high levels of nucleolar nucleolin is associated with a
better prognosis in pancreatic ductal adenocarcinoma patients
[25]; this further supporting the possibility that nucleolin has a
biologically functional role in tumours that progress to a more
malignant phenotype.
EMT is an indispensable process that is associated with normal
tissue development and organogenesis, as well as with tissue
remodeling and wound healing [19]. The involvement of EMT in
cancer metastasis is based on the observation that acquisition of
mesenchymal markers, such as vimentin or FSP1 by epithelial car-
cinoma cells is associated with increased metastatic potential, and
loss of epithelial cell adhesion molecules, such as E-cadherin
[2,24]. In this paper, we found that blocking cell surface distribu-
tion of nucleolin by treatment with speciﬁc inhibitor HB19 inhib-
ited the process of EMT, indicating that nucleolin located in cell
surface plays an important role in EMT. Thus inhibition of cell sur-
face nucleolin may be a promising theraputic approach for pre-
venting tumor metastasis.
In this paper, we showed that VEGF expression were corelated
with nucleolin distribution in clinical samples of colorectal carci-
noma. VEGF treatment promoted phosphorylation and re-location
of nucleolin through PI3K/Akt pathway in colorectal tumor cell
lines. Further the data showed that the distribution of nucleolin
was related to tumor metastasis both in clinical tumor samples
and in cellular models in vitro (Fig. 6). Our ﬁndings indicate that
D.-m. Wu et al. / FEBS Letters 588 (2014) 1921–1929 1929nucleolin may serve as a promising treatment target for colorectal
carcinoma.
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